MSP3 Biofusion is under clinical development by Vac4All and currently in Phase II for Malaria. According to GlobalData, Phase II drugs for Malaria have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MSP3 Biofusion’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MSP3 Biofusion overview
Vaccine candidate is under development for the prevention of malaria. It is administered through intramuscular route. It is a second generation vaccine candidate comprising merozoite surface protein-3 (MSP3) of Plasmodium falciparum that is being developed based on biofusion conjugate technology.
Vac4All overview
Vac4All is a biotechnology company that develops vaccines for the treatment of malaria. The company’s pipeline products antigens include Merozoite Surface Protein-3 (MSP3), Liver-Stage Antigen-3 (LSA3), and Liver-Stage Antigen-5 (LSA5) for the treatment of malaria. The company employs bio fusion conjugate technology and alum first formulation to develop its malaria vaccines. Vac4All is also exploring human immunity towards malaria to advance its pipeline candidates. The company is funded by Sentinext Therapeutics, Sanofi, and European Commission FP7 program. Vac4All is headquartered in Paris, Ile-de-France, France.
For a complete picture of MSP3 Biofusion’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
